Crispr used in mice to reverse vision loss đ.
Qin and colleagues develop a genome-editing tool characterized by the versatility of prime editors and unconstrained PAM requirement of SpRY. In vivo gene corre.
Category: biotech/medical – Page 629
Year 2020 Immortality in eyes achieved with Nad plus đđđ.
Glaucoma and age-related macular degeneration are leading causes of irreversible blindness worldwide with significant health and societal burdens. To date, no clinical cures are available and treatments target only the manageable symptoms and risk factors (but do not remediate the underlying pathology of the disease). Both diseases are neurodegenerative in their pathology of the retina and as such many of the events that trigger cell dysfunction, degeneration, and eventual loss are due to mitochondrial dysfunction, inflammation, and oxidative stress. Here, we critically review how a decreased bioavailability of nicotinamide adenine dinucleotide (NAD; a crucial metabolite in healthy and disease states) may underpin many of these aberrant mechanisms. We propose how exogenous sources of NAD may become a therapeutic standard for the treatment of these conditions.
While it has long been known that ultraviolet (UV) light can help kill disease-causing pathogens, the COVID-19 pandemic has put a spotlight on how these technologies can rid environments of germs. However, the excimer lamps and LEDs that can directly emit light in the required deep-UV wavelengths generally have low efficiency or suffer from short lifetimes. Moreover, UV light of the wrong wavelength can actually be harmful to human cells.
Now, a team led by researchers from Osaka University has shown how an optical device made of aluminum nitride can be used to generate deep-UV light in a method wholly different from previous approaches. The team made use of a process called âsecond harmonic generation,â which relies on the fact that the frequency of a photon, or particle of light, is proportional to its energy. The study is published in the journal Applied Physics Express.
Most transparent materials are considered âlinearâ with respect to their response to light, i.e., photons cannot interact with each other. However, inside certain ânonlinearâ materials, two photons can be combined into a single photon with twice the energy, and thus, twice the frequency.
Artificial intelligence (AI) is the term used to describe the use of computers and technology to simulate intelligent behavior and critical thinking comparable to a human being. John McCarthy first described the term AI in 1956 as the science and engineering of making intelligent machines.
This descriptive article gives a broad overview of AI in medicine, dealing with the terms and concepts as well as the current and future applications of AI. It aims to develop knowledge and familiarity of AI among primary care physicians.
PubMed and Google searches were performed using the key words âartificial intelligenceâ. Further references were obtained by cross-referencing the key articles.
More than half of all cardiovascular diseases worldwide have been found to be directly connected to five classic cardiovascular disease risk factors, with high blood pressure being the most significant factor related to heart attacks and strokes. Dr. Christie Ballantyne, professor of medicine, and Dr. Vijay Nambi, associate professor of medicine, both with Baylor College of Medicine, are co-authors along with a large group of scientists who make up the Global Cardiovascular Risk Consortium who recently published these findings in the New England Journal of Medicine.
The consortium, under the leadership of the University of Heart & Vascular Center of the Medical Center of Hamburg-Eppendorf and the German Center for Cardiovascular Research, used data from 112 studies consisting of 1.5 million people from 34 different countries.
The group reports that two conclusions can be made from these findings: The first, that more than half of all heart attacks and strokes can be prevented by understanding, treating or preventing the five classic risk factors: weight, high blood pressure, high cholesterol, smoking and diabetes. The second, that the other half of heart attacks and strokes cannot be explained with these risk factors and more work and research is needed to find additional causes.
Gastrointestinal (GI) disorders account for about 10% of all consultations in primary care and have a major impact on quality of life and health care resources. Gastro-oesophageal reflux disease (GERD), H. pylori infection, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), coeliac disease, antibiotic-associated diarrhea (ADA), infectious diarrhea, are some common GI disorders.
The efficacy of probiotics in preventing and treating gastrointestinal disorders has received considerable attention in recent years. This article will shed light on how probiotics are more or less effective in treating different gastrointestinal disorders.
Indian Burden and Factors Affecting GI Disorders The prevalence of self-reported gastrointestinal disorders in India is around 18%. Whereas the prevalence of gastroesophageal reflux disease (GERD) ranges from 2.5% to 7.1% in most population-based studies in Asia.
Malaria is one of the most widespread and devastating infectious diseases across the globe. This mosquito-borne parasitic disease killed approximately 619,000 people in 2021 alone, many of them children in Africa. In one of the deadliest forms of malaria, known as cerebral malaria, the patient experiences severe neurological symptoms, such as seizures and coma. Although only a small fraction of people who fall ill with malaria also experience cerebral malaria, the condition is lethal without treatment. Among hospitalized patients with the condition, death rates range between 15 and 20%. In a new paper, recently published in Science Translational Medicine, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and their colleagues studied children with cerebral malaria in Malawi to better understand the underlying causes of these devastating symptoms in the hope of developing improved treatments.
Researchers know that the symptoms of cerebral malaria are caused when the brain swells within the confines of the skull, eventually impinging upon the brainstem, which causes breathing to stop. However, researchers have been unsure how malaria infection leads to brain swelling. Some researchers hypothesized that the main cause was a weakening of the blood-brain barrier, which would allow fluid to seep into the brain and cause it to swell. Others speculated that the primary driver behind the swelling was inside the blood vessels themselves. Red blood cells infected with P. falciparum, the parasite which causes malaria, can become âsticky,â adhering to the walls of blood vessels. Partial blockages inside the cerebral veins could slow the flow of blood leaving the brain, causing the blood vessels themselves to become engorged and expand the brain from within.
To distinguish between these two hypotheses, NIAID researchers and their collaborators used non-invasive imaging techniques to study the flow of blood within the brains of 46 children who had been hospitalized for cerebral malaria at the Pediatric Research Ward of Queen Elizabeth Central Hospital in Blantyre, Malawi. As a comparison, they also studied 33 children with uncomplicated malaria and 26 healthy children from the local region. By using a light-based external monitoring tool (called near-infrared spectroscopy, or NIRS) the researchers were able to measure the amount of hemoglobin in the childrenâs brains. They reasoned that if excess fluid was the cause of brain swelling, then the hemoglobin concentration would be low, due to dilution. Alternatively, if the blood vessels were engorged with blood, then the hemoglobin concentration would be high.
Commercial platforms for protein therapeutics are being built on academic research that has expanded the genetic code behind cell-based translation.
Antibiotic resistance is a major danger to public health that threatens to claim the lives of millions of people per year within the next few decades. Years of necessary administration and excessive application of antibiotics have selected for strains that are resistant to many of our currently available treatments. Due to the high costs and difficulty of developing new antibiotics, the emergence of resistant bacteria is outpacing the introduction of new drugs to fight them. To overcome this problem, many researchers are focusing on developing antibacterial therapeutic strategies that are âresistance-resistantââregimens that slow or stall resistance development in the targeted pathogens. In this mini review, we outline major examples of novel resistance-resistant therapeutic strategies. We discuss the use of compounds that reduce mutagenesis and thereby decrease the likelihood of resistance emergence. Then, we examine the effectiveness of antibiotic cycling and evolutionary steering, in which a bacterial population is forced by one antibiotic toward susceptibility to another antibiotic. We also consider combination therapies that aim to sabotage defensive mechanisms and eliminate potentially resistant pathogens by combining two antibiotics or combining an antibiotic with other therapeutics, such as antibodies or phages. Finally, we highlight promising future directions in this field, including the potential of applying machine learning and personalized medicine to fight antibiotic resistance emergence and out-maneuver adaptive pathogens.
The use of antibiotics is central to the practice of modern medicine but is threatened by widespread antibiotic resistance (Centers for Disease Control and Prevention (U.S.), 2019). Antibiotics are a selective evolutionary pressureâthey inhibit bacterial growth and viability, and antibiotic-treated bacteria are forced to either adapt and survive or succumb to treatment. The stress of antibiotic treatment can enhance bacterial mutagenesis leading to de novo resistance mutations (Figure 1A), promote the acquisition of horizontally transferred genetic elements that confer resistance, or trigger phenotypic responses that increase tolerance to drugs (Davies and Davies, 2010; Levin-Reisman et al., 2017; Bakkeren et al., 2019; Darby et al., 2022;). Additionally, antibiotic treatment can select for the proliferation of pre-existing mutants already in the population (Figure 1B).
Research led by the Department of Anthropology and School of Biomedical Sciences, Kent State University, Ohio, has investigated neuropeptide Y innervation in an area of the brain called the nucleus accumbens of various primate species, including humans. The research was focused on understanding its role in brain evolution and any implications for human health, particularly regarding addiction and eating disorders.
In a paper, âHedonic eating, obesity, and addiction result from increased neuropeptide Y in the nucleus accumbens during human brain evolution,â published in PNAS, the researchers suggest that the combination of increased neuropeptide Y (NPY) and dopamine (DA) within the human nucleus accumbens (NAc) may have allowed for enhanced brain development. This same configuration may have also made humans exceptionally vulnerable to eating disorders and substance abuse, hinting at addictive traits having a deep evolutionary origin.
NPY plays a role in the reward system, emotional behavior and is associated with increased alcohol use, drug addiction and fat intake. The NAc brain region is central to motivation and action, exhibiting one of the highest densities of NPY in the brain and is of great interest to researchers investigating brain-related promoters of addiction.